Home / News

Novo Shares Jump 6% as Wegovy Pill Sales Beat Forecasts and Outlook Improves

• Novo Nordisk shares rose more than 6% after third-quarter sales hit 79.2 billion Danish kroner, beating FactSet estimates and boosting adjusted operating profit. • The drugmaker raised its outlook to adjusted revenue and operating profit growth between negative 2% and 2% at constant exchange rates for the year. • Wegovy pill sales reached 5.4 billion kroner, surpassing analyst estimates, while injectable Wegovy and Ozempic also exceeded expectations in the quarter. • Chief Financial Officer Karsten Munk Knudsen will leave at the end of 2026, with Luigi La Corte of Galderma named as his successor.

Novo Nordisk shares jumped more than 6% in early trading on Wednesday after the Danish pharmaceutical company reported third-quarter results that comfortably exceeded Wall Street expectations, led by strong sales of its newly launched Wegovy pill. The company said quarterly sales rose 4% year-on-year at constant exchange rates to 79.2 billion Danish kroner, or about $11.9 billion, ahead of FactSet consensus estimates of 73.6 billion kroner. Adjusted operating profit also surpassed forecasts, reaching 31.7 billion kroner against an expected 28.6 billion kroner. The beat marked a sharp reversal in sentiment after a difficult year in which Novo struggled to keep pace with rival Eli Lilly in the fast-growing weight-loss drug market. Novo also raised its full-year guidance, signaling growing confidence in the momentum behind its GLP-1 franchise. The company now expects adjusted revenue and operating profit growth of between negative 2% and 2% at constant exchange rates, an improvement from the negative 6% to flat range it had projected earlier in the year. The stronger outlook was underpinned by sales of the oral Wegovy pill, which totaled 5.4 billion kroner in the quarter, above the roughly 4.5 billion kroner analysts had forecast. Injectable Wegovy and the diabetes treatment Ozempic also performed better than expected, generating 20.4 billion kroner and 29.7 billion kroner, respectively. The results arrive amid intensifying competition in the obesity and diabetes drug space, where Novo pioneered the modern GLP-1 category but has faced criticism for losing share to Lilly in the United States. Investors are increasingly focused on next-generation weight-loss treatments and their potential to address obesity-linked conditions such as cardiovascular disease, kidney disease, sleep apnea and arthritis. Novo’s recovery narrative has also been complicated by a September selloff, when shares fell nearly 8% after the company failed to reassure investors about its growth strategy beyond Wegovy. Despite the latest beat, Chief Executive Mike Doustdar cautioned that a single strong quarter was not enough to declare a full turnaround, while noting that repeated guidance upgrades gave him confidence in the company’s direction. Novo also announced a leadership change in its finance department, with Chief Financial Officer Karsten Munk Knudsen leaving at the end of 2026 after 27 years at the company, including nine years in the top finance role. Luigi La Corte, currently chief financial officer at Swiss dermatology company Galderma, will succeed him. The earnings update followed Eli Lilly’s decision last week to raise its own full-year outlook on strong demand for Mounjaro and Zepbound, although Lilly’s weight-loss pill Foundayo missed expectations. For Novo, the combination of a better-than-expected quarter, upgraded guidance and renewed investor confidence offered a welcome sign that its comeback in the GLP-1 market may finally be gaining traction, even as shares remain down roughly 17% year-to-date.